Healx Ltd. Raises $56 Million to Use Artificial Intelligence to Sped Up Rare Disease Drug Trials
Seanbatty / Pixabay

Healx Ltd. Raises $56 Million to Use Artificial Intelligence to Sped Up Rare Disease Drug Trials

As originally reported in South Africa Latest News, Healx Ltd. has raised $56 million dollars to fund their development of treatment options for rare diseases using artificial intelligence. The British…

Continue Reading Healx Ltd. Raises $56 Million to Use Artificial Intelligence to Sped Up Rare Disease Drug Trials

After 120 Drug Failures, Can this be the Drug to Slow Alzheimer’s Progression?

  Over the years Alzheimer’s patients and their families have seen more than one hundred twenty drugs that were developed for the treatment of Alzheimer's have failed. For a while,…

Continue Reading After 120 Drug Failures, Can this be the Drug to Slow Alzheimer’s Progression?
First Patient Dosed in Clinical Trial of Cystic Fibrosis with Severe Exocrine Pancreatic Insufficiency
derneuemann / Pixabay

First Patient Dosed in Clinical Trial of Cystic Fibrosis with Severe Exocrine Pancreatic Insufficiency

According to a story from BioSpace, the biopharmaceutical company AzuRx BioPharma Inc. recently announced that the first patient has been treated in the company's phase 2 clinical trial. This trial…

Continue Reading First Patient Dosed in Clinical Trial of Cystic Fibrosis with Severe Exocrine Pancreatic Insufficiency
ICYMI: This Mother Showed Doctors Videos of Her Son Chatting and Running Around Before he Regressed. They Finally Found an Answer 12 Years Later
kittyflake / Pixabay

ICYMI: This Mother Showed Doctors Videos of Her Son Chatting and Running Around Before he Regressed. They Finally Found an Answer 12 Years Later

As originally reported on NPR, Alex Yiu’s mom has a montage of her son's early years. As one watches the videos, you see something: him losing control. He begins to…

Continue Reading ICYMI: This Mother Showed Doctors Videos of Her Son Chatting and Running Around Before he Regressed. They Finally Found an Answer 12 Years Later
An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial
Free-Photos / Pixabay

An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial

According to a story from globenewswire.com, the experimental drug somatrogon, which is being co-developed by Pfizer, Inc. and OPKO Health, Inc., was able to achieve its primary endpoint in a…

Continue Reading An Experimental Treatment for Growth Hormone Deficiency Performs Well in Phase 3 Trial
Man with Cystic Fibrosis Goes From 24/7 Oxygen Tank to an Avid Biker 24 Years After his Lung Transplant
source: pixabay.com

Man with Cystic Fibrosis Goes From 24/7 Oxygen Tank to an Avid Biker 24 Years After his Lung Transplant

  When Frankie Avila first got his lung transplant, he was told that, like most organs that are transplanted, his lungs only have a certain amount of time before they…

Continue Reading Man with Cystic Fibrosis Goes From 24/7 Oxygen Tank to an Avid Biker 24 Years After his Lung Transplant
Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug
sbtlneet / Pixabay

Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug

According to a story from BioSpace, Oncotelic, Inc., recently announced the publication of a study in the Journal of Clinical Research in Pediatrics. This study appears to back up the therapeutic…

Continue Reading Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug

Study Shows Tysabri Reduces Risk of Cognitive Decline for Pediatric-Onset Multiple Sclerosis Patients

The Gap Tysabri is a therapy that has shown efficacy for reducing disease activity in patients diagnosed with pediatric-onset multiple sclerosis (POMS). Previous investigations have indicated that up to 58%…

Continue Reading Study Shows Tysabri Reduces Risk of Cognitive Decline for Pediatric-Onset Multiple Sclerosis Patients
FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension
jarmoluk / Pixabay

FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension

According to a story from MDMag, the US Food and Drug Administration (FDA) has recently approved a label expansion for the drug treprostinil (marketed as Orentiram). This update to the…

Continue Reading FDA Announces Label Expansion for Treprostinil to treat Pulmonary Arterial Hypertension
New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects
source: pixabay.com

New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects

  CNN recently covered a story in the publication Nature about a paper explaining base editing (or prime editing). The researchers who created the technology set forth the process of using base…

Continue Reading New Prime Editing Has The Potential to Search and Replace up to 89% of Genetic Defects
11 Year Old Aims to Spread Awareness about Primary Pulmonary Hypertension, a Rare Disease That has Ravaged Her Family
Free-Photos / Pixabay

11 Year Old Aims to Spread Awareness about Primary Pulmonary Hypertension, a Rare Disease That has Ravaged Her Family

According to a story from the Borehamwood & Elstree Times, the family of 11 year old girl Sivan Hermon is plagued by a rare disease: primary pulmonary hypertension. As the…

Continue Reading 11 Year Old Aims to Spread Awareness about Primary Pulmonary Hypertension, a Rare Disease That has Ravaged Her Family
“I Could Die:” Vocalist from The Script Talks About Wilson’s Disease Diagnosis
Free-Photos / Pixabay

“I Could Die:” Vocalist from The Script Talks About Wilson’s Disease Diagnosis

According to a story from irishmirror.ie, Danny O'Donoghue, the vocalist and keyboard player for the Irish rock band The Script, recently talked publicly about his struggle with Wilson's disease, a…

Continue Reading “I Could Die:” Vocalist from The Script Talks About Wilson’s Disease Diagnosis
Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis
source: pixabay.com

Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis

According to a story from Ankylosing Spondylitis News, findings from a phase 3 clinical trial suggest that the drug secukinumab (marketed as Cosentyx) could be an effective treatment for non-radiographic…

Continue Reading Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis